4.5 Article

Gastrointestinal symptoms predictors of health-related quality of life in pediatric patients with functional gastrointestinal disorders

Journal

QUALITY OF LIFE RESEARCH
Volume 26, Issue 4, Pages 1015-1025

Publisher

SPRINGER
DOI: 10.1007/s11136-016-1430-3

Keywords

Irritable bowel syndrome; Functional constipation; Functional abdominal pain; Gastrointestinal symptoms; Patient-reported outcomes; PedsQL

Funding

  1. Takeda Pharmaceuticals North America, Inc. (Deerfield, Illinois)
  2. Takeda Pharmaceuticals North America, Inc.
  3. INSPPIRE to Study Acute Recurrent and Chronic Pancreatitis is Children [10987759]
  4. National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases
  5. NIH [R01 NR013497, T32 DK007664, K24DK082792A]

Ask authors/readers for more resources

To investigate the patient-reported multidimensional gastrointestinal symptoms predictors of generic health-related quality of life (HRQOL) in pediatric patients with functional gastrointestinal disorders (FGIDs). The Pediatric Quality of Life Inventory (TM) (PedsQL (TM)) Gastrointestinal Symptoms Scales and PedsQL (TM) 4.0 Generic Core Scales were completed in a 9-site study by 259 pediatric patients with functional constipation, functional abdominal pain (FAP), or irritable bowel syndrome (IBS). Gastrointestinal Symptoms Scales measuring stomach pain, stomach discomfort when eating, food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea were identified as clinically important symptom differentiators from healthy controls based on prior findings, and subsequently tested for bivariate and multivariate linear associations with overall HRQOL. Gastrointestinal symptoms were differentially associated with decreased HRQOL in bivariate analyses for the three FGIDs. In predictive models utilizing hierarchical multiple regression analyses controlling for age, gender, and race/ethnicity, gastrointestinal symptoms differentially accounted for an additional 47, 40, and 60 % of the variance in patient-reported HRQOL for functional constipation, FAP, and IBS, respectively, reflecting large effect sizes. Significant individual gastrointestinal symptoms predictors were identified after controlling for the other gastrointestinal symptoms in the FGID-specific predictive models. Gastrointestinal symptoms represent potentially modifiable predictors of generic HRQOL in pediatric patients with FGIDs. Identifying the condition-specific gastrointestinal symptoms that are the most important predictors from the patient perspective facilitates a patient-centered approach to targeted interventions designed to ameliorate impaired overall HRQOL.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available